Cara Therapeutics, Inc. (NASDAQ:CARA) Given Average Rating of “Hold” by Brokerages

Shares of Cara Therapeutics, Inc. (NASDAQ:CARA) have been assigned an average recommendation of “Hold” from the five brokerages that are presently covering the company, MarketBeat reports. Five analysts have rated the stock with a hold rating. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $27.84.

Separately, StockNews.com started coverage on shares of Cara Therapeutics in a research note on Wednesday, January 8th. They issued a “sell” rating for the company.

Cara Therapeutics Stock Performance

Shares of CARA stock opened at $5.01 on Tuesday. The stock has a market capitalization of $22.90 million, a P/E ratio of -0.24 and a beta of 0.50. The company has a 50 day moving average price of $4.97 and a 200 day moving average price of $4.07. Cara Therapeutics has a fifty-two week low of $2.71 and a fifty-two week high of $13.80.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CARA. FMR LLC lifted its position in shares of Cara Therapeutics by 18.5% during the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after buying an additional 32,789 shares during the last quarter. Rockefeller Capital Management L.P. purchased a new stake in shares of Cara Therapeutics during the 4th quarter worth approximately $953,000. XTX Topco Ltd purchased a new stake in shares of Cara Therapeutics during the 3rd quarter worth approximately $29,000. Shay Capital LLC purchased a new stake in shares of Cara Therapeutics during the 4th quarter worth approximately $524,000. Finally, Curi RMB Capital LLC purchased a new stake in shares of Cara Therapeutics during the 4th quarter worth approximately $277,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.